Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling

CDH1 deficiency is common in diffuse gastric cancer and triple negative breast cancer patients, both of which still lack effective therapeutics. ROS1 inhibition results in synthetic lethality in CDH1-deficient cancers, but often leads to adaptive resistance. Here, we demonstrate that upregulation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jiaming, Yao, Yunying, Liu, Chenxuan, Xie, Xi, Li, Donghe, Liu, Ping, Wang, Zaiqi, Zhang, Baoyuan, Ren, Ruibao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266074/
https://www.ncbi.nlm.nih.gov/pubmed/37324948
http://dx.doi.org/10.7150/ijbs.81918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266074/
https://www.ncbi.nlm.nih.gov/pubmed/37324948
http://dx.doi.org/10.7150/ijbs.81918

Ejemplares similares